| Company* (Country; Symbol) |
Product | Description | Indication | Status (Date) |
| AUTOIMMUNE | ||||
| Archimedes Pharma Ltd.* (UK) | IN Diazepam | Intranasal product | Epilepsy | Showed high bioavailability, positive pharmacokinetics and good tolerability in a Phase I study (2/26) |
| Zealand Pharma A/S* (Denmark) | ZP1848 | A glucagon-like peptide-2 agonist | Crohn's disease | Started a Phase I trial (2/3) |
| CANCER | ||||
| AVEO Pharmaceuticals Inc.* | AV-951 | VEGF receptor inhibitor | Breast cancer | Began a Phase Ib/IIa trial (2/19) |
| BN Immuno-Therapeutics Inc. (subsidiary of Bavarian Nordic A/S; Denmark; CSE:BAVA) | MVA-BN- HER2 | Vaccine focused on tumors that over express HER2 | Breast cancer | Phase I/II study met its primary endpoint; the vaccine was well tolerated with no severe adverse events (2/23) |
| Celsion Corp. (CLSN) | ThermoDox | A liposomal encapsulation of doxorubicin | Chest wall breast cancer | Started a pivotal Phase I/II study (2/10) |
| Cytopia Ltd. (Australia; ASX:CYT) | CYT997 | An anticancer vascular-disrupting agent | Cancer | Concluded dose escalation in its oral Phase I study (2/5) |
| EntreMed Inc. (ENMD) | ENMD-2076 | An Aurora A/angiogenic kinase inhibitor | Solid tumors | Phase I data showed it was well tolerated (2/9) |
| EUSAPharma* | Quadramet | Samarium Sm-153 lexidro-nam injection | Multiple myeloma | Phase I data of Quadramet in combination with Velcade showed responses among patients who were failing Velcade-based therapy; some patients achieved complete responses (2/11) |
| GTx Inc. (GTXI) | GTx-758 | An oral luteinizing hormone inhibitor | Advanced prostate cancer | Started a Phase I trial (2/23) |
| Keryx Bio-pharmaceuticals Inc. (KERX) | KRX-0401 | Perifosine | Multiple myeloma | Phase I/II data of KRX-0401 in combination with Velcade with or without dexamethasone showed a median time to progression of 8.5 months for patients who previously relapsed on a bortezomib-based treatment (2/26) |
| Medivation Inc. (MDVN) | MDV3100 | An androgen receptor antagonist | Castration-resistant prostate cancer | Phase I/II data showed the drug consistently demonstrated anti-tumor activity across dose levels and endpoints (2/26) |
| Nektar Therapeutics Inc. (NKTR) | NKTR-105 | A PEGylated form of docetaxel | Solid tumors | The first patients have been dosed in a Phase I study (2/17) |
| Nerviano Medical Sciences* (Italy) | | Antitumoral agent that blocks Cdc7 | Cancer | Received FDA approval to conduct Phase I trials (2/10) |
| Northwest Biotherapeutics Inc. (OTC BB:NWBO) | DCVax-Brain | A personalized immuno-therapy for cancer that is made from a patient's own dendritic cells and antigens from the patient's own tumor tissue | Glioblastoma multiforme | Phase I and Phase I/II data showed that none of the patients died during the evaluation period and that 68% lived more than 24 months (2/17) |
| OncoGenex Pharmaceuticals Inc. (OGXI) | OGX-011 | Uses second-generation antisense technology to target clusterin | Non-small-cell lung cancer | Phase I/II data showed a two-year survival rate of 30% when it was used with chemotherapy, compared with historical rates of 23% with Avastin and chemo-therapy and 15% with chemo-therapy alone (2/4) |
| CARDIOVASCULAR | ||||
| Inspiration Bio-pharmaceuticals Inc.* | IB1001 | An intravenous recombinant Factor IX product | Hemophilia B | Began a Phase I trial (2/12) |
| Osiris Therapeutics Inc. (OSIR) | Prochymal | Formulation of adult mesenchymal stem cells | Acute myocardial infarction | Phase I data showed patients had lower rates of adverse events and significantly improved heart function (2/12) |
| CENTRAL NERVOUS SYSTEM | ||||
| Archimedes Pharma Ltd.* (UK) | IN Apomorphine | Intranasal product | Parkinson's disease | Showed high bioavailability, positive pharmacokinetics and good tolerability in a Phase I study (2/26) |
| Corcept Therapeutics Inc. (CORT) | Corlux | A GRII receptor antagonist | Psychotic depression and Cushing's syndrome | Data showed the addition of Corlux to Risperdal in healthy subjects resulted in a statistically significant reduction in weight gain compared to those receiving Risperdal alone (2/2) |
| Depomed Inc. (DEPO) | DM-1992 | Gastric retentive extended-release dosage form of Levodopa/Carbidopa | Parkinson's disease | Dosed the first patient in a Phase I trial (2/17) |
| TorreyPines Therapeutics Inc. (TPTX) | NGX426 | An AMPA/kainate-type glutamate receptor antagonist | Pain | Oral administration was safe and well tolerated in a Phase I trial (2/11) |
| DIABETES | ||||
| Genaera Corp. (GENR) | MSI-1436 | Trodusquemine; highly selective inhibitor of PTP1B | Type II diabetes and obesity | Phase Ib data demonstrated meaningful improvement in four primary outcomes used to evaluate Type II diabetes (2/10) |
| Isis Pharmaceuticals Inc. (ISIS) | SGLT2Rx | Kidney-targeted antisense drug | Type II diabetes | Started a Phase I study (2/5) |
| INFECTION | ||||
| Achaogen Inc.* | ACHN-490 | Bactericidal agent | Complicated urinary tract infections | Started a Phase I trial (2/3) |
| Cubist Pharmaceuticals Inc. (CBST) | CB-183,315 | An antibacterial drug | Clostridium-difficile-associated diarrhea | Started dosing in the first trial (2/13) |
| Cubist Pharmaceuticals Inc. (CBST) | CB-182,804 | A bactericidal IV therapy | Multidrug-resistant Gram-negative infections | Began dosing in the first-in-human trial (2/17) |
| Enanta Pharmaceuticals Inc.* | ABT-450 | An oral protease inhibitor | Chronic hepatitis C virus | Began a first-in-human study (2/18) |
| Enzon Pharmaceuticals Inc. (ENZN) | rhMBL | Recombinant human Mannose-Binding Lectin | To prevent severe infections in patients with multiple myeloma or undergoing liver transplant | Company is discontinuing development because it did not meet criteria in Phase Ib trials (2/10) |
| Hawaii Biotech Inc.* | | West Nile virus vaccine | West Nile virus | Phase I data showed it had a favorable profile with no serious adverse events (2/25) |
| ImQuest Life Sciences* | IQP-0410 | Dual-acting pyrimidinedione HIV inhibitor | HIV | Data showed it is well tolerated and safe with plasma drug concentrations tenfold to twenty-fold greater than those required for complete suppression of HIV replication at 24 hours following oral administration (2/9) |
| Novavax Inc. (NVAX) | | Pandemic influenza virus-like particle vaccine candidate | H5N1 A/Indonesia/05/2005 avian influenza strain | Phase I/IIa data showed it induced robust hemagglutination inhibition responses (2/17) |
| Sangamo BioSciences Inc. (SGMO) | SB-728-T | Based on the company's zinc finger DNA-binding protein nuclease technology | HIV/AIDS | Started a Phase I trial (2/3) |
| Vical Inc. (VICL) | | Monovalent and trivalent Vaxfectin-formulated H5N1 pandemic flu DNA vaccines | Influenza | Phase I data showed they were safe and well tolerated and induced antibody responses and T-cell responses against a matching strain of influenza virus (2/13) |
| MISCELLANEOUS | ||||
| AVI BioPharma Inc. (AVII) | AVI-4658 | Based on the company's Exon-Skipping Pre-RNA Interference Technology | Duchenne muscular dystrophy platform | Treated the first patient in a trial with 16 ambulatory boys (2/19) |
| Cardium Therapeutics Inc. (AMEX:CXM) | | DNA-based approach that introduces a normal adenosine deaminase gene into the hematopoietic stem cells of children | Severe combined immuno-deficiency | All 10 children in the study survived, and the gene therapy was not associated with any adverse events during a median follow- up of four years (2/3) |
| ESBATech AG* (Switzerland) | ESBA105 | A single-chain antibody fragment directed against TNF-alpha; topically applied | For patients undergoing cataract surgery | Started a Phase Ib/IIa study (2/3) |
| Gilead Sciences Inc. (GILD) | GS 9350 | Pharmacoenhancing agent | To increase blood levels and allow once-daily dosing for certain medicines | Phase I data showed it has significant pharmacoenhancing ability; it also boosted elvitegravir (2/9) |
| Isotechnika Inc. (Canada; TSX:ISA) and Lux Biosciences* | LX214 | A topical ophthalmic solution containing voclosporin | Dry eye syndrome and other chronic inflammatory ocular surface diseases | Began treating patients in a Phase I study (2/17) |
| Medgenics Inc. (UK; LSE:MEDG) | Epodure Biopump | A toothpick-sized protein factory derived from a patient's own tissue | Anemia in patients with chronic kidney disease | Phase I/II data showed it sustained elevation of hemoglobin in most patients (2/3) |
| Nymox Pharmaceutical Corp. (NYMX) | NX-1207 | Investigational agent for BPH | Benign prostatic hyperplasia | Phase I/II data showed sustained improvement in BPH symptom score (2/24) |
| Penwest Pharmaceuticals Co. (PPCO) | A0001 | A coenzyme Q10 analogue | Mitochondrial diseases | Started dosing in a Phase Ib trial (2/25) |
| QRxPharma Ltd. (Australia; PK: QRXPY) | MoxDuo IR | Immediate release capsules | For patients who have undergone total knee replacement surgery | Started a comparative three-arm pilot study (2/19) |
| Sequoia Pharmaceuticals* | SPI-452 | A novel pharmacokinetic enhancer with no inherent antiviral activity | To enhance HIV protease inhibitors | Phase I data showed it substantially enhanced the products and was generally safe and well tolerated, with few side effects (2/9) |
|
Notes: * Privately held. Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; TSX = Toronto Stock Exchange. | ||||
